Revenue

At EHA 2026, Parexel isn't just presenting data; it's unveiling a bold new strategy to fix a broken system and accelerate life-saving blood cancer drugs.

An expanded partnership between GENESIS Pharma and Alnylam is set to bring revolutionary RNAi therapies to the Nordics. But can it navigate the region's tough economic hurdles?

evyAI is offering its full AI sales agent for free until summer 2026, challenging the subscription model. We dig into the strategy, the risks, and what it means for you.

As the Indian media giant turns ten, its biggest bet isn't on the big screen. A deep dive into its massive microdrama acquisition and global strategy.

With only 4% of US pets insured despite soaring vet costs, a new partnership signals a major shift. Is embedding insurance the key to this untapped market?

The asset manager's May report reveals $3.3B in net inflows, driven by a major target date fund win, underscoring its market resilience and leadership.

New clinical data suggests Cullinan Therapeutics' cancer-fighting tech could offer durable, treatment-free remission for severe RA and lupus patients.

The viral foldable home company BOXABL has secured its Nasdaq listing via a SPAC merger. But with a massive valuation and minimal cash from the deal, can it deliver?

Greenland Mines secures a strategic foothold in Iceland, betting on green energy and brownfield revival to build a vital North Atlantic supply chain.

Danish industrial firm TRESU slashes its 2026 revenue forecast, citing a slowdown. But with profits stable, is this a company-specific issue or a warning for the entire printing machinery sector?

With $100M in contracts just five months post-launch, Dapple’s funding isn't just capital—it's a powerful market signal for a new 'fourth option' in AI.

With $101M from top VCs, Ethyreal Bio emerges from stealth to target the root cause of both Graves' Disease and Thyroid Eye Disease with a single antibody.

TELUS enters Ontario's crowded TV market with Optik TV, betting on flexible streaming and channel bundles to woo customers from established rivals.

A landmark deal sees Novartis invest up to $1.4B in Orionis Biosciences' AI platform, aiming to turn the chance discovery of 'molecular glue' drugs into a science.

With a new imec partnership and a global HQ, Park Systems is betting big on leading the critical measurement tools needed for the next era of 3D semiconductors.

APA Corporation's $70M acquisition of aging Alaskan infrastructure seems modest, but it's a masterclass in modern energy strategy, revealing how pipelines, not just prospects, are the real prize.

TELUS brings its Optik TV and PureFibre service to Montreal and Quebec City, challenging incumbents Bell and Videotron with flexible, bundled entertainment.

CIBC's new SpaceX CDR offers Main Street a ticket to the final frontier of investing. But is it a leap for investor democracy or a step into the unknown?

Latest drill results from Brunswick Exploration’s Anatacau project reveal major lithium potential, sparking comparisons to its flagship Mirage asset.

New data shows car prices moderating and incentives rising, yet record-high SUV costs and stubborn affordability issues reveal a complex reality for buyers.